Pulmonx Corp Dossier
Qualitative Analysis
Business overview
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company specializing in minimally invasive treatments for patients with severe emphysema, a progressive form of chronic obstructive pulmonary disease (COPD). The company's flagship solution is the Zephyr Endobronchial Valve, a one-way implant placed bronchoscopically to block airflow to the most diseased parts of the lung, thereby reducing hyperinflation and allowing healthier lung tissue to function more effectively. This interventional therapy is paired with the Chartis Pulmonary Assessment System, which measures collateral ventilation to predict treatment success, and the StratX Lung Analysis Platform, a cloud-based quantitative CT analysis service that assists in patient selection and procedural planning. Pulmonx operates in a specialized interventional pulmonology market, positioning its products as a standard of care that bridges the gap between medical management and highly invasive surgical options.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing on filling open sales positions, implementing a refocused commercial strategy, and driving sales productivity to expand Zephyr Valve utilization at existing centers.
Expected impact: Gradual improvement in sales productivity and a return to year-over-year growth in the U.S. market in the second half of 2026.
Advancing the CONVERT II clinical trial to evaluate the safety and effectiveness of the AeriSeal System in blocking collateral ventilation (CV) and converting severe emphysema patients from CV+ to CV- status, making them eligible for Zephyr Valve treatment.
Expected impact: Expanding the global addressable patient population for Zephyr Valves by up to 20%.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired the assets of Aeris Therapeutics, including the AeriSeal foam-based lung sealant system, to expand the treatable patient population for Pulmonx's emphysema therapies.
Financial impact: Transaction value was not publicly disclosed. The technology serves as the foundation for Pulmonx's long-term market expansion strategy.
Strategic Partnerships
Integrates advanced data qualification capabilities directly into Jaeger's SentrySuite software platform for respiratory diagnostics. This streamlines diagnostic workflows and helps clinicians more easily identify severe emphysema patients who may qualify for Zephyr Valve treatment.
Terms: Financial terms of the partnership were not disclosed.
Collaborating on educational initiatives, patient stories, and expert Q&A sessions to raise awareness about advanced COPD/emphysema treatment options, including the Zephyr Valve, among patients and healthcare providers.
Terms: Financial terms were not disclosed.